Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05285839 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05285839 · ClinicalTrials.gov record · last posted 2024-03-15

Dupixent and Narrowband UVB for Atopic Dermatitis

StatusRecruiting
PhasePhase 4
Started2022-04-19
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 15, 2024 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2022-03-08; most recent amendment 2025-01-08. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-01-08
Status change Recruiting→Completedv2
2024-03-14
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05285839
Lead Sponsor Psoriasis Treatment Center of Central New Jersey
Collaborators: Regeneron Pharmaceuticals
Conditions Atopic Dermatitis
Enrollment 40 participants
Start Date 2022-04-19
Primary Completion 2024-12-01 (estimated)
Study Completion 2024-12-15 (estimated)
Updated on ClinicalTrials.gov 2024-03-15